1. Home
  2. TCI vs IMMP Comparison

TCI vs IMMP Comparison

Compare TCI & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Transcontinental Realty Investors Inc.

TCI

Transcontinental Realty Investors Inc.

HOLD

Current Price

$53.75

Market Cap

487.3M

Sector

Finance

ML Signal

HOLD

Logo Immutep Limited

IMMP

Immutep Limited

HOLD

Current Price

$2.77

Market Cap

426.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TCI
IMMP
Founded
1983
1987
Country
United States
Australia
Employees
N/A
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
487.3M
426.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TCI
IMMP
Price
$53.75
$2.77
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.7K
174.9K
Earning Date
03-19-2026
02-22-2026
Dividend Yield
N/A
N/A
EPS Growth
75.87
N/A
EPS
0.65
N/A
Revenue
$48,675,000.00
$3,306,742.00
Revenue This Year
N/A
$292.48
Revenue Next Year
N/A
N/A
P/E Ratio
$82.69
N/A
Revenue Growth
N/A
31.28
52 Week Low
$26.02
$1.32
52 Week High
$59.65
$3.53

Technical Indicators

Market Signals
Indicator
TCI
IMMP
Relative Strength Index (RSI) 50.30 49.00
Support Level $53.57 $2.56
Resistance Level $54.56 $2.83
Average True Range (ATR) 0.82 0.15
MACD -0.08 -0.03
Stochastic Oscillator 48.17 39.81

Price Performance

Historical Comparison
TCI
IMMP

About TCI Transcontinental Realty Investors Inc.

Transcontinental Realty Investors Inc is a fully integrated externally managed real estate company. It operates multifamily and commercial properties throughout the southern United States and also invests in mortgage notes receivable and in the land that is either held for appreciation or development. The company has two business segments: the acquisition, development, ownership, and management of multifamily properties which include the rental of apartments (Residential Segment) and other tenant services, including parking and storage space rental, and the acquisition, development, ownership, and management of commercial properties which are office properties(Commercial Segment). It includes the rental of office space and other tenant services, including parking and storage space rental.

About IMMP Immutep Limited

Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

Share on Social Networks: